ULK1 as a novel therapeutic target in neurodegeneration

作     者：Björn Friedhelm Vahsen Paul Lingor Bj?rn Friedhelm Vahsen;Paul Lingor

作者机构：Nuffield Department of Clinical NeurosciencesUniversity of OxfordJohn Radcliffe HospitalOxfordUK Department of NeurologyUniversity Medical Center GöttingenGöttingenGermany Center for Biostructural Imaging of Neurodegeneration(BIN)DFG Cluster of Excellence Nanoscale Microscopy and Molecular Physiology of the Brain(CNMPB)University Medical Center GöttingenGöttingen Department of NeurologyRechts der Isar Hospital of the Technical University MunichMunichGermany 

出 版 物：《Neural Regeneration Research》 (中国神经再生研究（英文版）)

年 卷 期：2021年第16卷第6期

页      面：1212-1213页

核心收录：

学科分类：0710[理学-生物学] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100204[医学-神经病学] 10[医学] 

基　　金：supported by a scholarship from the Department of Neurology University Medical Center Göttingen.PL received funding from the Cluster of Excellence and DFG Research Center Nanoscale Microscopy and Molecular Physiology of the Brain(CNMPB) Göttingen 

主　　题：degeneration therapeutic neurodegeneration 

摘      要：Axonal degeneration is an early and key pathophysiological feature of many traumatic and neurodegenerative disorders of the central nervous system(CNS),such as spinal cord injury(SCI),Parkinson’s disease(PD),and amyotrophic lateral sclerosis(ALS).As the regenerative capacity of injured axons is severely restricted in the CNS,axonal degeneration frequently results in the irreversible loss of neuronal connections causing progressive neurological deficits and clinical disability.A better understanding of the mechanisms of axon degeneration is therefore hoped to unravel new therapeutic avenues to combat neurodegeneration(Lingor et al.,2012).